Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Mejia A (Principal Investigator)
Summary
Methodist Health System is conducting a prospective registry study collecting real-world outcomes data on PRRT treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study tracks patient characteristics, treatment responses, survival outcomes, and adverse events in patients treated with PRRT, including Ga-68 DOTATATE PET/CT imaging data. Enrollment target is 50 patients, currently recruiting at Dallas, TX.
Clinical Significance
PRRT with DOTATATE is an increasingly important therapeutic modality for GEP-NETs, and real-world registry data complements the pivotal NETTER-1 trial. This study provides additional evidence on long-term outcomes, which is critical for expanding PRRT access and reimbursement in community oncology settings.
Key Findings:
- Prospective registry tracking PRRT outcomes in GEP-NET patients
- Key endpoints: overall survival, time to progression, biomarker response (chromogranin A, pancreastatin)
- Ga-68 DOTATATE PET/CT used for patient selection (Krenning score)
- Inclusion: Ki67 < 20%, metastatic/locally advanced, octreotide-positive tumors
- Currently recruiting, estimated completion June 2026
Clinical Takeaway: For oncologists managing GEP-NETs, this registry provides ongoing real-world evidence on PRRT outcomes. DOTATATE-based PRRT continues to establish itself as a standard option for somatostatin receptor-positive tumors.
Links:
Powiązane badania
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…